文献速递病毒性肝炎艾滋病与性传播感染

美国注射吸毒者扩展网络中丙型肝炎病毒治疗即预防的建模研究

Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study.
PubMed 文献 · Lancet Infect Dis · 2017-11-15

该建模研究基于美国哈特福德1574名注射吸毒者的数据,模拟不同HCV治疗覆盖率(0%、3%、6%、12%、24%)和基线HCV患病率(30%、60%、75%、85%)下治疗即预防策略对10年和20年HCV患病率的影响。模型估计显示,基线HCV患病率为85%时扩大治疗覆盖不显著降低患病率;基线患病率≤60%时,每年每1000名注射吸毒者治疗超过120人(12%)可能在10年内消除HCV。

要点

  • 基线HCV患病率≤60%时,每年治疗超过12%的注射吸毒者可能在10年内消除HCV。
  • 基线HCV患病率高达85%时,任何治疗即预防策略均不显著降低HCV患病率。
  • 随机分配治疗平均优于针对注射伙伴最多者,治疗额外网络成员可增强效果。

核心结论

  • 成功的HCV治疗即预防应结合基线HCV患病率,并在覆盖率足够扩大时获益最大。

研究设计与样本

  • 基于美国哈特福德1574名注射吸毒者数据的网络建模研究,拟合五个图模型并选用度校正随机块模型模拟HCV和HIV传播。

主要发现

  • 基线HCV患病率85%时,扩大治疗覆盖对任何治疗即预防策略均不显著降低HCV患病率。
  • 基线HCV患病率60%或更低时,每年每1000名注射吸毒者治疗超过120人(12%)可能在10年内消除HCV。
  • 随机分配治疗平均优于针对注射伙伴最多者。
  • 治疗额外网络成员的治疗即预防策略表现最佳,并可增强针对网络内度数(即注射伙伴最多)的较弱策略。

关键数值与推荐

  • 模拟的治疗覆盖率水平为0%、3%、6%、12%、24%。
  • 模拟的基线HCV患病率水平为30%、60%、75%、85%。
  • 比较七种治疗即预防策略在10年和20年降低HCV患病率的效果与不治疗相比。

临床怎么用

  • 在基线HCV患病率≤60%的注射吸毒者人群中,可考虑将治疗覆盖率扩大至每年每1000人超过120人(12%)以实现10年内消除HCV。
  • 治疗即预防策略应优先随机分配治疗而非仅针对注射伙伴最多者,并考虑治疗额外网络成员。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic infections with hepatitis C virus (HCV) and HIV are highly prevalent in the USA and concentrated in people who inject drugs. Treatment as prevention with highly effective new direct-acting antivirals is a prospective HCV elimination strategy. We used network-based modelling to analyse the effect of this strategy in HCV-infected people who inject drugs in a US city. METHODS: Five graph models were fit using data from 1574 people who inject drugs in Hartford, CT, USA. We used a degree-corrected stochastic block model, based on goodness-of-fit, to model networks of injection drug users. We simulated transmission of HCV and HIV through this network with varying levels of HCV treatment coverage (0%, 3%, 6%, 12%, or 24%) and varying baseline HCV prevalence in people who inject drugs (30%, 60%, 75%, or 85%). We compared the effectiveness of seven treatment-as-prevention strategies on reducing HCV prevalence over 10 years and 20 years versus no treatment. The strategies consisted of treatment assigned to either a randomly chosen individual who injects drugs or to an individual with the highest number of injection partners. Additional strategies explored the effects of treating either none, half, or all of the injection partners of the selected individual, as well as a strategy based on respondent-driven recruitment into treatment. FINDINGS: Our model estimates show that at the highest baseline HCV prevalence in people who inject drugs (85%), expansion of treatment coverage does not substantially reduce HCV prevalence for any treatment-as-prevention strategy. However, when baseline HCV prevalence is 60% or lower, treating more than 120 (12%) individuals per 1000 people who inject drugs per year would probably eliminate HCV within 10 years. On average, assigning treatment randomly to individuals who inject drugs is better than targeting individuals with the most injection partners. Treatment-as-prevention strategies that treat additional network members are among the best performing strategies and can enhance less effective strategies that target the degree (ie, the highest number of injection partners) within the network. INTERPRETATION: Successful HCV treatment as prevention should incorporate the baseline HCV prevalence and will achieve the greatest benefit when coverage is sufficiently expanded. FUNDING: National Institute on Drug Abuse.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Zelenev A, Li J, Mazhnaya A, et al. Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study. Lancet Infect Dis. 2017. PMID: 29153265. doi:10.1016/S1473-3099(17)30676-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。